{"product_id":"btai-business-model-canvas","title":"(BTAI) BioXcel Therapeutics, Inc. Business Model Canvas Research","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-List-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBioXcel Therapeutics: Business Model Canvas Snapshot\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eUnlock the full strategic blueprint behind BioXcel Therapeutics, Inc.’s business model. This concise Business Model Canvas reveals how the company creates value, manages partnerships, and positions itself in a competitive biotech market. Perfect for investors, analysts, and strategists seeking actionable insight—download the full version to go deeper.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003ePartnerships\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eFDA and other regulators\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eBioXcel Therapeutics, Inc. depends on the FDA and other regulators for IGALMI® oversight, label updates, and safety monitoring, since the product is already commercial and every change in use must stay aligned with agency rules. The pipeline also needs active FDA engagement for BXCL501, BXCL502, and BXCL701, where approval timing and data packages can shift value fast.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eClinical trial investigators and sites\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eBioXcel Therapeutics, Inc. relies on hospital, clinic, and specialist research partners to run neuroscience and oncology studies, and these sites are the main channel for patient enrollment in agitation, dementia, depression, and cancer programs. In 2025, this network supported late-stage clinical work for BXCL501 and BXCL701 across multiple investigator-led trial locations.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eContract manufacturers and suppliers\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eBioXcel Therapeutics, Inc. depends on contract manufacturers and suppliers to make IGALMI, its only approved sublingual film, and to support future pipeline candidates. That external capacity lowers the need for owned plants, but it also makes supply continuity a core risk for commercialization and late-stage development.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eWholesalers and specialty distributors\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eBioXcel Therapeutics, Inc. relies on wholesalers and specialty distributors to move hospital-use agitation treatments through pharmacy channels, handling ordering, inventory, and delivery to care sites. For inpatient psychiatry and emergency settings, these partners are key because rapid access can decide whether treatment starts on time.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eSupport hospital ordering and stocking\u003c\/li\u003e\n\u003cli\u003eManage cold-chain and delivery flow\u003c\/li\u003e\n\u003cli\u003eSpeed access for acute agitation care\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eThis channel is built for reach and speed, not direct selling, so BioXcel Therapeutics, Inc. depends on distributor coverage to keep product available where clinicians treat severe agitation.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eAcademic and medical center collaborators\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eAcademic and medical center collaborators help BioXcel Therapeutics, Inc. validate new indications, recruit patients, and build clinical evidence for AI-enabled drug re-innovation. They also add neuroscience and oncology depth, which matters in a pipeline built around programs like BXCL501 and BXCL701 and helps make the data more credible to regulators and investors.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eValidate new uses with real patients\u003c\/li\u003e\n\u003cli\u003eStrengthen neuroscience and oncology expertise\u003c\/li\u003e\n\u003cli\u003eBoost trust in AI-led development\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBioXcel’s 2025 Growth Hinges on Key Partners\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eBioXcel Therapeutics, Inc. depends on 4 partner groups: the FDA, contract manufacturers, distributors, and academic or medical centers. In 2025, those ties supported 1 approved product, IGALMI®, and 3 pipeline programs, while keeping clinical work and supply outside the company’s own plants.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003ePartner\u003c\/th\u003e\n\u003cth\u003eWhy it matters\u003c\/th\u003e\n\u003cth\u003e2025 data\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eFDA\u003c\/td\u003e\n\u003ctd\u003eApproval, label, safety\u003c\/td\u003e\n\u003ctd\u003e1 commercial product\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eManufacturers\u003c\/td\u003e\n\u003ctd\u003eIGALMI supply\u003c\/td\u003e\n\u003ctd\u003e1 approved film\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAcademic sites\u003c\/td\u003e\n\u003ctd\u003eTrial enrollment\u003c\/td\u003e\n\u003ctd\u003e3 pipeline programs\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"product-includes\"\u003e\n\u003cdiv class=\"product-includes__container\"\u003e\n\u003ch2 id=\"product-includes-title\" class=\"product-includes__title\"\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-includes__grid\"\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Detailed Word Document icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eA concise, real-company Business Model Canvas for BioXcel Therapeutics, covering its drug-development strategy, partnerships, and investor-focused value proposition.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Customizable Excel Spreadsheet icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eQuickly spot BioXcel Therapeutics’ business model pain points with a clear, one-page canvas.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Reference-Icon.svg\" alt=\"References icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eReference Sources\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eBioXcel Therapeutics, Inc. Reference Sources provide a traceable credibility trail that supports faster, more confident decision-making.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eActivities\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAI-driven drug re-innovation\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eBioXcel uses proprietary machine learning to scan thousands of known compounds for new uses, making drug re-innovation the core of its neuroscience and immuno-oncology strategy. Starting from clinically validated molecules cuts early discovery risk and can speed time to proof of concept.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eClinical development\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eBioXcel Therapeutics runs 3 clinical programs—BXCL501, BXCL502, and BXCL701—across 5 areas: agitation, depression, dementia, prostate cancer, and solid tumors. Clinical data generation is the core work here, because every study reads on approval, label expansion, and the next value step for Company Name.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRegulatory execution\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eBioXcel Therapeutics' regulatory execution centers on filings, FDA responses, and safety updates for one approved product, IGALMI, plus pipeline assets like BXCL501 and BXCL701. In Q1 2025, the Company reported $6.2 million in revenue, so keeping approved use and future label expansions aligned with regulators is core to both near-term sales and long-term value.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eCommercialization of IGALMI\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eBioXcel Therapeutics, Inc. centers commercialization on IGALMI, its only marketed product, for rapid treatment of agitation in adults with schizophrenia or bipolar I or II disorder. Key work is market access, prescriber education, and demand generation; as of 2025, the approved sublingual film comes in 120 mcg and 180 mcg strengths.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eDrive payer coverage\u003c\/li\u003e\n\u003cli\u003eTrain prescribers fast\u003c\/li\u003e\n\u003cli\u003eBuild acute-care demand\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eManufacturing and supply oversight\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eBioXcel Therapeutics, Inc. has to tightly control film quality and inventory for IGALMI, its 120 mcg and 180 mcg sublingual films, because acute-care use leaves little room for delays or batch issues. Reliable supply supports both hospital buying decisions and clinician confidence, while any shortage can directly hit revenue from each dispensed dose.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eQuality control must stay consistent.\u003c\/li\u003e\n\u003cli\u003eInventory must cover urgent demand.\u003c\/li\u003e\n\u003cli\u003eSupply reliability protects revenue and trust.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBioXcel’s Q1 Revenue Hinges on Trial and Label Progress\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eBioXcel Therapeutics, Inc.’s key activities are AI-led drug re-innovation, clinical development, and regulatory execution for IGALMI, BXCL501, BXCL502, and BXCL701. In Q1 2025, Company Name reported $6.2 million in revenue, so trial progress and label work remain the main value drivers.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eActivity\u003c\/th\u003e\n\u003cth\u003e2025 data\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eCommercialization\u003c\/td\u003e\n\u003ctd\u003eIGALMI; $6.2 million Q1 revenue\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eClinical trials\u003c\/td\u003e\n\u003ctd\u003e3 programs across 5 areas\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eProduct supply\u003c\/td\u003e\n\u003ctd\u003e120 mcg and 180 mcg films\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003ePreview Before You Purchase\u003c\/span\u003e\u003cbr\u003e Business Model Canvas\u003c\/h2\u003e\n\u003cp\u003eThis BioXcel Therapeutics, Inc. Business Model Canvas preview is taken directly from the final document, so what you see here is exactly what you’ll receive after purchase. It is not a mockup or sample—it's the same professionally formatted file, ready to use. Once you buy, you’ll download this identical document with the full content intact.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Resources-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eResources\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eProprietary machine learning platform\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eBioXcel Therapeutics’ proprietary machine learning platform is a core internal asset that scans large drug and biology data sets to find new uses for existing compounds, which helps shorten discovery time and lowers early R\u0026amp;D risk. That AI-led approach sets BioXcel apart from traditional biopharma models that rely more on slower, lab-heavy target discovery.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eIGALMI approved asset\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eIGALMI is BioXcel Therapeutics, Inc.'s first commercial product, so it gives the company a validated market presence and real-world usage data. It also anchors current revenue and brand recognition, while the FDA approval provides a key reference point for the business model.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Resources-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBXCL501 development program\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eBXCL501 is BioXcel Therapeutics, Inc.'s lead neuroscience asset and the core value driver in its pipeline. Beyond its approved use for agitation, it is being studied in Alzheimer’s disease, depression, and community settings, broadening the addressable market and the company’s commercial upside.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eBXCL502 and BXCL701 pipeline\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eBioXcel Therapeutics’ key resources include 2 pipeline assets: BXCL502 for chronic agitation in dementia and BXCL701, an oral innate immunity activator for prostate cancer and advanced solid tumors. Together, they broaden the Company Name’s pipeline across 2 therapeutic areas and create 2 distinct shots on goal.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eBXCL502: dementia agitation\u003c\/li\u003e\n\u003cli\u003eBXCL701: oncology, oral agent\u003c\/li\u003e\n\u003cli\u003e2 therapeutic areas, 1 pipeline\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eClinical data and intellectual property\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eBioXcel Therapeutics relies on clinical data, formulation know-how, and patent cover to keep BXCL501 and IGALMI differentiated. Its value is tied to trial readouts and FDA milestones, because one positive study or label expansion can shift a capital-heavy biotech’s valuation fast.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eTrial data drives approvals\u003c\/li\u003e\n\u003cli\u003ePatents defend exclusivity\u003c\/li\u003e\n\u003cli\u003eKnow-how supports formulation\u003c\/li\u003e\n\u003cli\u003eValuation hinges on milestones\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBioXcel’s Value Hinges on AI, IGALMI, and Pipeline Readouts\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eBioXcel Therapeutics’ key resources are its AI drug-engine platform, IGALMI, and a small but focused pipeline. As of the latest filing, the Company Name had 1 marketed product, 2 lead pipeline assets, and 2 core therapeutic areas, so value still hinges on data readouts, FDA steps, and cash runway.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eResource\u003c\/th\u003e\n\u003cth\u003eWhy it matters\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eAI platform\u003c\/td\u003e\n\u003ctd\u003eFinds new uses fast\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eIGALMI\u003c\/td\u003e\n\u003ctd\u003eCommercial proof\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eBXCL501, BXCL502, BXCL701\u003c\/td\u003e\n\u003ctd\u003ePipeline upside\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Value-Propositions-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eValue Propositions\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRapid agitation control\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eIGALMI delivers dexmedetomidine as a sublingual film for rapid control of agitation in adults with schizophrenia or bipolar I or II disorder. It gives a non-injectable option when quick calming matters, with the film designed for use in acute episodes and a labeled dose of 120 mcg or 180 mcg.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAI-based drug re-innovation\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eBioXcel Therapeutics, Inc. turns approved molecules into new treatments, so it starts with lower discovery risk than de novo drug design. The Company has 1 FDA-approved product, IGALMI, and uses the same AI-led platform to reuse that chemistry across new indications.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Value-Propositions-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eConvenient sublingual administration\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eThe sublingual film gives BioXcel Therapeutics, Inc. a simple, noninvasive option for acute psychiatric settings: IGALMI comes in 120 mg and 180 mg strengths and dissolves without IV or IM setup. That can save staff time and reduce handling steps, which matters when care teams need fast, repeatable use.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003ePipeline expansion beyond current label\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eBXCL501 is being tested in agitation tied to Alzheimer’s disease, add-on depression use, and community settings, so one core molecule can reach 3 adjacent markets. That matters because it can widen the label beyond hospital use and stretch the product life cycle; BioXcel Therapeutics, Inc. is still building on the same active drug, dexmedetomidine.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e3 expansion paths for BXCL501\u003c\/li\u003e\n\u003cli\u003eBroader market reach\u003c\/li\u003e\n\u003cli\u003eLonger product life\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eOncology opportunity with BXCL701\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eBXCL701 gives BioXcel Therapeutics, Inc. a shot at aggressive prostate cancer and other advanced solid tumors, adding a second commercial lane beyond neuroscience. Prostate cancer caused about 375,000 deaths worldwide in 2022, and the global immuno-oncology market topped $110 billion in 2024, so a PD-L1–linked innate immune approach could widen BioXcel Therapeutics, Inc.'s reach.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eTargets aggressive prostate cancer\u003c\/li\u003e\n\u003cli\u003eExtends into advanced solid tumors\u003c\/li\u003e\n\u003cli\u003eCreates a second commercial lane\u003c\/li\u003e\n\u003cli\u003eSupports an immuno-oncology foothold\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBioXcel’s value: one approved asset, two high-upside pipeline bets\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eBioXcel Therapeutics, Inc. value comes from one approved, rapid-use asset and two pipeline bets. IGALMI offers noninvasive agitation control in schizophrenia and bipolar I or II disorder, while BXCL501 and BXCL701 extend the same platform into Alzheimer’s agitation, depression, and solid tumors.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eAsset\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eIGALMI\u003c\/td\u003e\n\u003ctd\u003e1 FDA-approved product\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eBXCL501\u003c\/td\u003e\n\u003ctd\u003e3 expansion paths\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eBXCL701\u003c\/td\u003e\n\u003ctd\u003eProstate cancer and solid tumors\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Relationships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eCustomer Relationships\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDirect medical engagement\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eBioXcel Therapeutics needs direct, high-touch engagement with prescribers and hospital buyers because IGALMI is used in acute-care settings, where adoption depends on fast education and trust. In 2025, the company still had to win bedside clinicians and pharmacy committees one site at a time, since hospital formulary decisions can move faster than broad retail launches.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMedical affairs support\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eBioXcel Therapeutics, Inc. relies on medical affairs to explain IGALMI’s trial evidence, 180 mcg and 120 mcg dosing, and safety in a product built on known dexmedetomidine. The team also supports congress and investigator talks, which matters when scientific trust drives adoption in acute agitation care.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Relationships-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAccount-based hospital access\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eBioXcel Therapeutics needs account-based hospital access because hospitals and health systems make formulary and procurement calls, not consumers. With about 6,000 U.S. hospitals to navigate, the model depends on structured account management, contracting, and clinical-economic proof to win access and keep it.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eClinical trial collaboration\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eBioXcel Therapeutics, Inc. keeps investigators and enrolled patients at the center of clinical trial collaboration, because each study visit adds evidence for new indications and FDA discussions. In 2025, this relationship remained vital to both science and credibility as the Company advanced late-stage programs built on real patient data.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eInvestigators drive trial quality.\u003c\/li\u003e\n\u003cli\u003ePatients generate approval data.\u003c\/li\u003e\n\u003cli\u003eCollaboration supports credibility.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003ePost-marketing safety monitoring\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eBioXcel Therapeutics, Inc. must keep tracking adverse events after IGALMI use, because ongoing safety reporting supports safer acute psychiatric care and helps sustain trust with prescribers and regulators. The FDA approved IGALMI in 2022 for acute agitation tied to schizophrenia or bipolar I disorder, so real-world monitoring remains part of the product’s commercial duty.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eTracks adverse events after launch\u003c\/li\u003e\n\u003cli\u003eSupports provider and regulator confidence\u003c\/li\u003e\n\u003cli\u003eHelps safe use in acute agitation care\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHow BioXcel Wins Hospital Trust for IGALMI\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eBioXcel Therapeutics, Inc. builds customer ties through direct hospital account work, medical affairs, and investigator support, because IGALMI is bought by health systems and used in acute-care units. The relationship is evidence-led: FDA-approved in 2022, IGALMI is sold in 180 mcg and 120 mcg doses, so prescriber trust and formulary access drive use.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eCustomer\u003c\/th\u003e\n\u003cth\u003eNeed\u003c\/th\u003e\n\u003cth\u003e2025\/2026 note\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eHospital buyers\u003c\/td\u003e\n\u003ctd\u003eFormulary access\u003c\/td\u003e\n\u003ctd\u003eAccount-based selling\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eClinicians\u003c\/td\u003e\n\u003ctd\u003eFast, safe use\u003c\/td\u003e\n\u003ctd\u003eMedical affairs support\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eInvestigators\u003c\/td\u003e\n\u003ctd\u003eTrial execution\u003c\/td\u003e\n\u003ctd\u003eClinical data generation\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Channels-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eChannels\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHospital pharmacy access\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eIGALMI is built for hospital and acute-care settings, so pharmacy placement is the main path to patient access. This channel fits inpatient and emergency use, where fast prescribing and stocking can matter more than retail reach.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePrescriber-driven sales\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003ePhysicians and psychiatric specialists drive BioXcel Therapeutics, Inc.'s IGALMI use, so field teams must reach the clinicians who treat acute agitation in schizophrenia and bipolar I\/II. The product comes in 120 mcg and 180 mcg doses, so account coverage and education matter at the prescriber level.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Channels-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMedical science liaison networks\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eBioXcel Therapeutics, Inc. uses medical science liaison networks to support scientific exchange, so MSLs can explain trial data and answer evidence questions for clinicians. This channel matters most as the Company Name expands its pipeline, where complex data and frequent study updates need clear, peer-level communication.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eClinical trial networks\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eClinical trial networks are BioXcel Therapeutics, Inc.’s main channel for recruiting patients and generating evidence for BXCL501, BXCL502, and BXCL701. In 2025, the company still relied on specialist sites to reach eligible groups fast and to support registrational data across CNS and oncology programs.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e\u003cp\u003eDirect access to specialists\u003c\/p\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cp\u003eFaster patient recruitment\u003c\/p\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cp\u003eHigher-quality clinical evidence\u003c\/p\u003e\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eConferences and digital education\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eBioXcel Therapeutics uses conferences and digital education to reach clinicians and researchers, which is standard for specialty biopharma and avoids direct consumer marketing. In its latest annual filing, the Company reported only limited revenue and stayed focused on scientific awareness, so congress talks, peer-to-peer content, and online materials help support physician education at low cost per contact.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eReach clinicians and researchers\u003c\/li\u003e\n\u003cli\u003eBuild awareness without DTC ads\u003c\/li\u003e\n\u003cli\u003eFits specialty biopharma norms\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHow BioXcel Reaches Hospitals and Trial Sites\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eBioXcel Therapeutics, Inc. reaches IGALMI mainly through hospital pharmacy stocking and specialist prescribers, since acute agitation is treated in inpatient and emergency settings. MSLs, congresses, and digital education support clinician trust, while trial sites remain key for BXCL501, BXCL502, and BXCL701 recruitment.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eChannel\u003c\/th\u003e\n\u003cth\u003eUse\u003c\/th\u003e\n\u003cth\u003eData point\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eHospital pharmacy\u003c\/td\u003e\n\u003ctd\u003eIGALMI access\u003c\/td\u003e\n\u003ctd\u003e120 mcg, 180 mcg\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eClinical trial sites\u003c\/td\u003e\n\u003ctd\u003ePatient recruitment\u003c\/td\u003e\n\u003ctd\u003e2025 pipeline focus\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Segments-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eCustomer Segments\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAdults with schizophrenia agitation\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAdults with schizophrenia-related agitation are a core IGALMI target, since the film is built for rapid calming in acute episodes; IGALMI became BioXcel Therapeutics, Inc.’s first commercial product after its 2022 launch and is FDA-approved for adults with schizophrenia or bipolar I disorder agitation.\u003c\/p\u003e\n\u003cp\u003eThis segment matters because agitation in schizophrenia often needs fast, noninvasive treatment in the first minutes to hours, and IGALMI is positioned to fill that gap in emergency and inpatient settings.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAdults with bipolar I or II agitation\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eBioXcel Therapeutics, Inc. also targets adults with bipolar I or II disorder who develop acute agitation, a segment covered by the same approved IGALMI sublingual film. This broadens the addressable pool beyond schizophrenia; the World Health Organization says about 40 million people worldwide live with bipolar disorder.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Segments-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePatients with Alzheimer’s or dementia agitation\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eBioXcel Therapeutics, Inc. targets patients with Alzheimer’s or dementia-related agitation through BXCL501 and BXCL502, aiming at a major unmet need in neuropsychiatry. With over 55 million people living with dementia worldwide and agitation affecting roughly 40% to 60% of cases, success here could open a much larger commercial market for BioXcel Therapeutics, Inc.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eOncology patients with aggressive tumors\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eBXCL701 targets oncology patients with aggressive tumors, especially metastatic castration-resistant prostate cancer and advanced solid tumors, moving BioXcel Therapeutics, Inc. into immuno-oncology. Prostate cancer caused about 397,000 deaths worldwide in 2022, so this is a distinct, high-need therapeutic customer base.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eBXCL701: aggressive prostate cancer\u003c\/li\u003e\n\u003cli\u003eAdvanced solid tumors\u003c\/li\u003e\n\u003cli\u003eSeparate immuno-oncology segment\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eHospitals and health systems\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eHospitals and health systems are the key buyer for BioXcel Therapeutics, Inc.'s acute agitation offer because purchasing, formulary access, and reimbursement usually sit with the institution, not the patient. For a hospital-based product like Igalmi, that makes medical staff, pharmacy committees, and payers central to adoption and use.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eInstitution-led buying drives access\u003c\/li\u003e\n\u003cli\u003eFormulary placement shapes utilization\u003c\/li\u003e\n\u003cli\u003eReimbursement affects hospital uptake\u003c\/li\u003e\n\u003cli\u003eAcute agitation needs fast hospital use\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBioXcel’s Core Markets: Hospitals, Dementia Care, and Oncology\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eBioXcel Therapeutics, Inc. serves three main customer groups: hospitals treating acute schizophrenia or bipolar I agitation with IGALMI, caregivers and clinicians in dementia-related agitation, and oncology teams for BXCL701 in aggressive tumors. The biggest buying power sits with hospitals and health systems, since formulary access and reimbursement drive use.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eSegment\u003c\/th\u003e\n\u003cth\u003eNeed\u003c\/th\u003e\n\u003cth\u003eUse case\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eAcute agitation\u003c\/td\u003e\n\u003ctd\u003eFast calming\u003c\/td\u003e\n\u003ctd\u003eIGALMI in hospitals\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDementia agitation\u003c\/td\u003e\n\u003ctd\u003eHigh unmet need\u003c\/td\u003e\n\u003ctd\u003eBXCL501\/BXCL502\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOncology\u003c\/td\u003e\n\u003ctd\u003eTumor control\u003c\/td\u003e\n\u003ctd\u003eBXCL701 trials\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Cost-Structure-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eCost Structure\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eResearch and development spend\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eBioXcel Therapeutics, Inc. still puts most of its cash into research and development, with discovery, translational work, and pipeline advancement as recurring costs. In its latest reported year, R\u0026amp;D remained the main operating spend, which is typical for a commercial-stage biopharma company that must keep funding new-label work and next-gen assets.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eClinical trial costs\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eBioXcel Therapeutics, Inc. says clinical development and regulatory work drive R\u0026amp;D spend; patient enrollment, site payments, monitoring, and data management are the biggest trial costs. With multiple active programs, the burden stacks fast, and late-stage studies are the most capital intensive because they run larger, longer, and across more sites.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Cost-Structure-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eManufacturing and supply costs\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eBioXcel Therapeutics, Inc. relies on quality-controlled manufacturing for IGALMI and pipeline materials, so production spend is tied to strict GMP standards and batch release testing. External manufacturing and packaging add both fixed and variable costs, and any supply break can hit commercial sales fast because IGALMI depends on steady product availability.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eSales and market access costs\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eBioXcel Therapeutics, Inc. had $17.9 million of revenue in 2024, and sales and market access costs remain tied to IGALMI adoption: field reps, hospital education, and payer reimbursement support all rise as promotion expands. For a launch-stage product, these costs are not optional; they are the spend that opens access and drives prescribing.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eField teams support hospital uptake\u003c\/li\u003e\n\u003cli\u003eEducation drives protocol use\u003c\/li\u003e\n\u003cli\u003eReimbursement work eases access\u003c\/li\u003e\n\u003cli\u003eCosts scale with promotion\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eIn 2024, BioXcel Therapeutics, Inc. still needed this spend to convert IGALMI awareness into orders, especially in hospital settings where access and coverage can slow sales.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eGeneral and administrative costs\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eGeneral and administrative costs at BioXcel Therapeutics, Inc. cover public-company overhead: legal, finance, HR, SEC reporting, and patent upkeep. These costs also support the New Haven headquarters structure, so they are a fixed base that rises when compliance, filings, or IP work get heavier.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eLegal, finance, HR, reporting\u003c\/li\u003e\n\u003cli\u003ePatent and regulatory compliance\u003c\/li\u003e\n\u003cli\u003eSupports New Haven HQ\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBioXcel’s Cost Base Is R\u0026amp;D-Heavy, with 2024 Revenue at $17.9M\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eBioXcel Therapeutics, Inc. keeps cost structure centered on R\u0026amp;D, with clinical trials, regulatory work, and manufacturing taking the largest share. In 2024, revenue was $17.9 million, while sales, G\u0026amp;A, and public-company overhead stayed lean but necessary to support IGALMI and pipeline progress.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eItem\u003c\/th\u003e\n\u003cth\u003e2024\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eRevenue\u003c\/td\u003e\n\u003ctd\u003e$17.9M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMain cost driver\u003c\/td\u003e\n\u003ctd\u003eR\u0026amp;D\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Revenue-Streams-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eRevenue Streams\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eIGALMI product sales\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eIGALMI is BioXcel Therapeutics, Inc.'s only commercial revenue stream and first monetized asset, with sales from its FDA-approved treatment for acute agitation in adults with schizophrenia or bipolar I or II disorder. In FY2025, it remained the base of the company’s product revenue, but sales were still early-stage and concentrated in this single asset.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eFuture BXCL501 sales\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eBXCL501 could add sales beyond its current acute agitation use if BioXcel Therapeutics, Inc. wins labels for Alzheimer’s agitation, depression add-on use, and community settings. Each approval would widen the addressable market; for example, agitation affects a large share of the roughly 6.9 million Americans living with Alzheimer’s disease.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Revenue-Streams-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eFuture BXCL502 sales\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eIf BioXcel Therapeutics, Inc. develops BXCL502 successfully, it could add sales in dementia-related chronic agitation and give the neuroscience unit a second agitation-focused product. As of 2025\/2026, it is still a pipeline asset, so near-term revenue is nil, but it could extend the same market BioXcel Therapeutics, Inc. is targeting with BXCL501.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eFuture BXCL701 sales\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eBXCL701 is still a development-stage asset, so it does not generate oncology sales yet; if trials and approval succeed, it could add revenue from prostate cancer and advanced solid tumors, giving BioXcel Therapeutics, Inc. income beyond neuroscience. The revenue case is binary: no launch, no sales.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eTarget: prostate cancer\u003c\/li\u003e\n\u003cli\u003eAlso: advanced solid tumors\u003c\/li\u003e\n\u003cli\u003eCurrent oncology revenue: 0\u003c\/li\u003e\n\u003cli\u003eDiversifies beyond neuroscience\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eMilestones and partnership income\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eBioXcel Therapeutics, Inc. can earn upfront cash, milestone payments, and royalties if it signs partnerships, which is common in biopharma. In 2025, BioXcel’s revenue base was still limited, so these deal inflows could matter more than product sales as a bridge to funding.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eUpfront fees can fund trials\u003c\/li\u003e\n\u003cli\u003eMilestones reward progress\u003c\/li\u003e\n\u003cli\u003eRoyalties add long-tail income\u003c\/li\u003e\n\u003cli\u003ePartnerships can diversify cash flow\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBioXcel’s Revenue Stays IGALMI-Dependent as Pipeline Upside Builds\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eBioXcel Therapeutics, Inc.'s revenue in FY2025 still came mainly from IGALMI, the only commercial product, so the base is narrow and single-asset. Near-term upside depends on BXCL501 label expansion, while BXCL502 and BXCL701 are still pre-revenue; deal cash from upfronts, milestones, and royalties can bridge funding.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eStream\u003c\/th\u003e\n\u003cth\u003eFY2025 status\u003c\/th\u003e\n\u003cth\u003eRevenue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eIGALMI\u003c\/td\u003e\n\u003ctd\u003eCommercial\u003c\/td\u003e\n\u003ctd\u003eProduct sales\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eBXCL501\u003c\/td\u003e\n\u003ctd\u003ePipeline\u003c\/td\u003e\n\u003ctd\u003e0\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eBXCL502\u003c\/td\u003e\n\u003ctd\u003ePipeline\u003c\/td\u003e\n\u003ctd\u003e0\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eBXCL701\u003c\/td\u003e\n\u003ctd\u003ePipeline\u003c\/td\u003e\n\u003ctd\u003e0\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePartners\u003c\/td\u003e\n\u003ctd\u003ePotential\u003c\/td\u003e\n\u003ctd\u003eUpfront, milestones, royalties\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"DCF Analyst","offers":[{"title":"Default Title","offer_id":57234140791049,"sku":"btai-business-model-canvas","price":5.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0942\/8045\/0313\/files\/btai-business-model.webp?v=1785713742","url":"https:\/\/dcfanalyst.com\/products\/btai-business-model-canvas","provider":"DCF Analyst","version":"1.0","type":"link"}